文献速递肥胖与代谢综合征

新视野:肥胖是神经递质传递障碍吗?

New Horizons: Is Obesity a Disorder of Neurotransmission?
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本文探讨肥胖作为神经递质传递障碍的概念,综述调控能量稳态的脑通路及抗肥胖治疗靶点,并分析非典型抗精神病药、抗抑郁药和抗组胺药等影响神经递质的药物与体重的关系,旨在为内分泌学界提供理解肥胖病理生理的概念框架。

要点

  • 靶向神经系统的药理学干预可促进体重减轻。
  • 需权衡神经系统作为可持续肥胖治疗靶点的安全性。
  • 影响神经递质的药物与体重变化相关。

核心结论

  • 肥胖可被视为一种神经递质传递障碍,靶向神经系统促进体重减轻的药理学证据支持这一概念。

主要发现

  • 靶向神经系统的药理学干预可促进体重减轻。
  • 非典型抗精神病药、抗抑郁药和抗组胺药等影响神经递质的药物与体重相关。

临床怎么用

  • 为内分泌医生理解肥胖病理生理提供概念框架,关注神经递质通路及影响神经递质药物对体重的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity is a disease of the nervous system. While some will view this statement as provocative, others will take it as obvious. Whatever our side is, the pharmacology tells us that targeting the nervous system works for promoting weight loss. It works, but at what cost? Is the nervous system a safe target for sustainable treatment of obesity? What have we learned-and unlearned-about the central control of energy balance in the last few years? Herein we provide a thought-provoking exploration of obesity as a disorder of neurotransmission. We discuss the state of knowledge on the brain pathways regulating energy homeostasis that are commonly targeted in anti-obesity therapy and explore how medications affecting neurotransmission such as atypical antipsychotics, antidepressants, and antihistamines relate to body weight. Our goal is to provide the endocrine community with a conceptual framework that will help expending our understanding of the pathophysiology of obesity, a disease of the nervous system.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Caron A, Jane Michael N. New Horizons: Is Obesity a Disorder of Neurotransmission? J Clin Endocrinol Metab. 2021. PMID: 34117881. doi:10.1210/clinem/dgab421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。